Help us: Donate
Follow us on:
×

Menu

Back

Tag: Investment

January 05, 2021
Tina Woods is a UK-based founder of several social enterprises in healthcare and longevity and the author of the book Live Longer with AI, which we recently reviewed. In this interview, Tina shares valuable insights on how social entrepreneurship works in our field, what governments can and must do to promote healthy aging, and what...
December 24, 2020
In this presentation given at Ending Age-Related Diseases 2020, Dr. Alexandra Bause of Apollo Venture discusses biotech investment in an aging world, explaining current demographic trends, the multimorbidities associated with an aging population, and the need of healthspan-enhancing biotechnology to meet this need. She brings up the hallmarks of aging and suggests multiple methods of...
December 15, 2020
In this presentation given at Ending Age-Related Diseases 2020, Dr. Tyler Golato talked about his company, Molecule, highlighting the current problems with pharmaceutical development and offering a new, decentralized method of developing therapies. He discussed the well-known valley of death, the gap between the basic research of academia and the later-stage development of pharmaceutical companies....
November 06, 2020
At this panel from Ending Age-Related Diseases 2020, Javier Noris of Lifespan.io talks with Patrick Burgermeister of Kizoo Ventures, Reason of Repair Biotechnologies, Sergio Ruiz of Methuselah Labs, and Ronjon Nag of Institute R42 about the valley of death in biotech investment. Early-stage research is funded by universities and governments, and companies are funded by...
October 16, 2020
In his presentation at Ending Age-Related Diseases 2020, LEAF board member Javier Noris discussed the Longevity Impact Fund, the reasons why biotechnology funding has been lacking, the "valley of death" that must be crossed in order to fully fund early-stage research through the clinical trial process, and new ways in which venture capital can fund high-risk biotechnology ventures.
October 05, 2020
More and more investors are starting to get interested in technologies that are being developed to slow or even reverse aging as therapies are starting to reach human trials. Recently, I attended the Longevity Investors Conference to learn more about investments being made towards anti-aging research. A shift towards doing something about aging The current...